Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Knowledge and diversity the watchwords for Roche's early research

This article was originally published in Scrip

Executive Summary

The well-documented decline in Big Pharma's R&D productivity, in parallel with ever-escalating costs, has spurred the re-engineering of processes at many firms over the past few years. For Roche, ways of moving away from the old "attrition-based" model include the early adoption of new techniques to understand precise disease mechanisms and the pursuit of partnerships.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC013583

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel